title: Maternal antibody parameters of cattle and calves receiving EG95 vaccine to protect against Echinococcus granulosus.
abstract: Cattle may act as hosts for the transmission of the cestode parasite Echinococcus granulosus and play a role in transmission of the parasite leading to human cystic echinococcosis (CE). The recombinant EG95 vaccine has been shown to be able to protect cattle and other intermediate host species against CE. Ideally the immunisation of bovines against E. granulosus, using EG95 vaccine, should occur early in life so as to provide maximum protection against the establishment of hydatid cysts. Maternally derived antibody from vaccinated cows may provide some protection for the neonate, but may also interfere with the active response to vaccination. Experiments were undertaken to determine the optimal regime for protection of young cattle against CE. One group of pregnant cattle received 2 vaccinations of EG95 antigen+Quil A adjuvant two months and one month prior to calving. The control group of pregnant cattle were not vaccinated. Calves were either challenged with E. granulosus eggs at 4, 9, 13 or 17 weeks post-birth or were given their first vaccination at 8, 12 or 16 weeks post-birth. Sera obtained at regular intervals were tested by ELISA to assess the immunological response. All calves were experimentally challenged with E. granulosus eggs and subsequent necropsy confirmed the levels of protection. Maternal antibody was shown to protect calves to some extent for at least 17 weeks. Calves from vaccinated cows responded well serologically if the first vaccination was given at 8 or 12 weeks, but full protection against a challenge infection was achieved only if the first vaccination was delayed until 16 weeks after birth. Calves from non-vaccinated cattle also were not fully protected if the first vaccination was at 8 or 12 weeks, but were fully protected if the first vaccination was given when they were 16 weeks old. This suggests that immunological maturity is not acquired in calves until 4 or 5 months of age. No safety problems were observed following two vaccinations of 40 pregnant cows or 30 suckling calves.
authors.affiliation: AgResearch New Zealand Limited, Animal Health Division, Hopkirk, Research Institute, Grasslands Research Centre, Palmerston North, 4442, New Zealand. david.heath@xtreme.net.nz
authors.forename: David D
authors.initials: DD
authors.lastname: Heath
authors.forename: Christine
authors.initials: C
authors.lastname: Robinson
authors.forename: Marshall W
authors.initials: MW
authors.lastname: Lightowlers
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000831:Animals, Newborn; D000913:Antibodies, Protozoan / Q000097:blood*; D000947:Antigens, Helminth / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D002417:Cattle; D002418:Cattle Diseases / Q000517:prevention & control*; D004443:Echinococcosis / Q000517:prevention & control / Q000662:veterinary*; D005260:Female; D015801:Helminth Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D007112:Immunity, Maternally-Acquired; D011247:Pregnancy; D016052:Protozoan Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D062605:Quillaja Saponins; D012503:Saponins / Q000008:administration & dosage
chemical_list: D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000947:Antigens, Helminth; C446034:EG95 protein, Echinococcus granulosus; D015801:Helminth Proteins; D016052:Protozoan Vaccines; D062605:Quillaja Saponins; D012503:Saponins; C046386:Quil A